FDA Orange Book · active-ingredient family
Levoleucovorin
Levoleucovorin is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:KHAPZORY · NDA 211226
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
0
Exclusivity periods
Brand (NDA) products · powder
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| KHAPZORYRLD×2 | ACROTECH BIOPHARMA | NDA 211226 | — | Oct 19, 2018 |
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11541012 | Mar 25, 2039 | in 12 yr 11 mo | Product |
Levoleucovorin — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
